Morgan Stanley Initiates Coverage On Integra Lifesciences with Equal-Weight Rating, Announces Price Target of $59
Morgan Stanley analyst Drew Ranieri initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Equal-Weight rating and announces Price Target of $59.